The purpose of this study is to evaluate the safety and efficacy of an investigational drug called MT-8421 alone and when given with another drug, nivolumab, in patients with advanced cancer. Researchers also want to understand how the body handles MT-8421. There are 2 parts in this study. The goal of Part A is to find the highest tolerable dose of MT-8421 by itself and with nivolumab. A recommended dose of MT-8421 will then be determined in Part B. Both parts of the study will evaluate how well the study treatment works to treat the patient’s cancer. Nivolumab has been approved by the U.S. Food and Drug Administration (FDA) to treat many cancers.
What is the full name of this clinical trial?
MT-8421-001: A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-8421 as Monotherapy and in Combination with Nivolumab in Patients with Selected Advanced Solid Cancer Types